Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.
about
Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT ProcessCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Crescentic glomerulonephritis: data from the Spanish Glomerulonephritis Registry.Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitisDifferent responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditionsState of the art in the treatment of systemic vasculitides.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis.Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort.Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis ReferraClinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn.OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity.Impact of pre-existing co-morbidities on mortality in granulomatosis with polyangiitis: a cohort study.Association of Lupus Anticoagulant With Long-Term Damage Accrual in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail.Evaluation of damage in giant cell arteritis.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.The European Vasculitis Society 2016 Meeting Report.Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis.Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure.Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis.A cohort study of comorbidity in patients with granulomatosis with polyangiitis.Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.Unmet Needs in the Pathogenesis and Treatment of Vasculitides.Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis.Can granulomatosis with polyangiitis be diagnosed earlier in primary care? A case-control study.Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].End-stage renal disease in ANCA-associated vasculitis.Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.
P2860
Q26795465-7CD3F59D-646D-45DA-9FCF-8559D437D23FQ27025692-91D2B049-2244-4C6A-8941-0AE3CE238D63Q30893344-455A8394-D753-4D95-AD7F-F50D38ACB8AFQ35759180-621DBBF4-0C71-4BD0-909F-07836512B550Q36242872-EB966BAE-C797-49C6-900B-4AE38E994613Q36332824-71CDEBA6-D820-4EFF-8156-3EB502A9F9DCQ36746012-36F85574-707A-4A01-A49C-BB6F788E85DDQ38263514-5F185A69-9975-49D1-9220-7B660F3F117DQ38316279-B17C4572-409D-4C61-8670-70C26C8276CAQ38512570-346ED616-23FE-4FBC-B446-E4AA1ACE3C30Q38543360-AB69EAED-2A72-413A-981B-6493C1BE0626Q38571610-679DB135-DD20-48E8-9FAE-F9856C34035AQ38873411-6326B1FB-98E7-4F7D-8DFC-5D6EC6471AE2Q39088103-D78970CE-4249-4F8E-A3A9-88DA60CE4FBBQ40060881-C9F614CE-5C11-4996-AC5F-B455D6488437Q40067987-1E121985-735A-4BBB-AD99-7A40D3D8E829Q40266045-EA21699B-44CD-4E77-B69A-4774FE86418CQ40490916-9050E331-5D37-4CFD-AB86-57776B0189C3Q40657767-1773972B-0458-4AB7-8718-A8C6C2C191F4Q40684657-005EBBEA-8E4D-4859-BA49-8F6147F5D602Q41592598-12D23C8B-8F71-49CD-89F2-35C90503AA56Q42380186-F456623D-F14C-4DA2-9C95-B4AB1A6F2EBBQ43163913-7A8546CE-474F-41B6-8423-CF378B5703D9Q46097662-448928B2-3166-40A6-8CD9-F5722404CEA5Q47105115-37297597-F547-4B29-B4AB-F6EB8ADAAF29Q47107377-B2D23CB1-5A53-406C-8421-BF2CEA31EAECQ47148328-6F618738-F020-4FE0-8172-9486CA7438ECQ47552107-31EE2ADA-1124-401A-9B41-0F01F1EF9E87Q47619266-2F0C4847-C61A-42F0-9664-439E07AFB57EQ47728927-804555B5-6099-44BD-8A48-62F216D0B8EAQ48102349-93F963AC-F055-4E76-80EA-5723C909D0BEQ48592090-803280C0-537C-4835-A954-E02C7D3C2DEAQ49788662-FA2209E5-5679-4FD8-A2E3-5BC10837AEE2Q50014474-937AD26D-79B2-4C84-89B9-175BC782E3EAQ50065383-0628E820-D5AB-4FBC-97BF-86FF35C67CD5Q50076914-B234CC2C-2175-4334-BEF1-C8BA0689409DQ53513595-DE732CE5-D641-4C9B-ADBE-1A5AD89A939FQ55191066-0C03EA62-3072-4363-B6EB-FECC7D3F43C3
P2860
Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Damage in the anca-associated ...... up (EUVAS) therapeutic trials.
@ast
Damage in the anca-associated ...... up (EUVAS) therapeutic trials.
@en
type
label
Damage in the anca-associated ...... up (EUVAS) therapeutic trials.
@ast
Damage in the anca-associated ...... up (EUVAS) therapeutic trials.
@en
prefLabel
Damage in the anca-associated ...... up (EUVAS) therapeutic trials.
@ast
Damage in the anca-associated ...... up (EUVAS) therapeutic trials.
@en
P2093
P2860
P50
P1476
Damage in the anca-associated ...... oup (EUVAS) therapeutic trials
@en
P2093
David Jayne
Helen Doll
Joanna Robson
Kerstin Westman
Lorraine Harper
Ravi Suppiah
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-203927
P407
P577
2013-11-15T00:00:00Z